【火热】新华制药开拓新市场，抢食大涨29239%的明星药

米内网2025-08-19

精彩内容近日，山东新华制药联合南京集萃剂鼎医药提交了瑞舒伐他汀依折麦布片（I）的4类仿制上市申请。瑞舒伐他汀依折麦布片（I）是血脂调节复方制剂潜力产品，赛诺菲的原研产品2025年Q1在中国三大终端六大市场飙涨29239%。目前，新华制药暂无血脂调节复方制剂获批，公司有望开拓新市场。图1：新华制药最新申报的产品来源：CDE官网瑞舒伐他汀依折麦布片（I）是由瑞舒伐他汀（HMG-CoA还原酶抑制剂）和...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2560416923?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-19 16:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2560416923","market":"us","top_or_hot":-1,"title":"【火热】新华制药开拓新市场，抢食大涨29239%的明星药","media":"米内网","content":"<div>\n<p>精彩内容近日，山东新华制药联合南京集萃剂鼎医药提交了瑞舒伐他汀依折麦布片（I）的4类仿制上市申请。瑞舒伐他汀依折麦布片（I）是血脂调节复方制剂潜力产品，赛诺菲的原研产品2025年Q1在中国三大终端六大市场飙涨29239%。目前，新华制药暂无血脂调节复方制剂获批，公司有望开拓新市场。图1：新华制药最新申报的产品来源：CDE官网瑞舒伐他汀依折麦布片（I）是由瑞舒伐他汀（HMG-CoA还原酶抑制剂）和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819162427a49161be&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【火热】新华制药开拓新市场，抢食大涨29239%的明星药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【火热】新华制药开拓新市场，抢食大涨29239%的明星药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-19 16:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819162427a49161be&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容近日，山东新华制药联合南京集萃剂鼎医药提交了瑞舒伐他汀依折麦布片（I）的4类仿制上市申请。瑞舒伐他汀依折麦布片（I）是血脂调节复方制剂潜力产品，赛诺菲的原研产品2025年Q1在中国三大终端六大市场飙涨29239%。目前，新华制药暂无血脂调节复方制剂获批，公司有望开拓新市场。图1：新华制药最新申报的产品来源：CDE官网瑞舒伐他汀依折麦布片（I）是由瑞舒伐他汀（HMG-CoA还原酶抑制剂）和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819162427a49161be&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MID","symbol_name":"American Century Mid Cap Growth Impact ETF","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819162427a49161be&s=b","article_id":"2560416923","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250819162427a49161be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2560416923","pubTimestamp":1755590630,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容近日，山东新华制药联合南京集萃剂鼎医药提交了瑞舒伐他汀依折麦布片的4类仿制上市申请。瑞舒伐他汀依折麦布片是血脂调节复方制剂潜力产品，赛诺菲的原研产品2025年Q1在中国三大终端六大市场飙涨29239%。目前，新华制药暂无血脂调节复方制剂获批，公司有望开拓新市场。表1：今年以来新华制药获批的新产品来源：米内网中国上市药品数据库","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"MID":"American Century Mid Cap Growth Impact ETF"},"translate_title":"[Hot] Xinhua Pharmaceutical opens up new markets and grabs star drugs that have soared by 29239%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MID":1},"content_text":"精彩内容近日，山东新华制药联合南京集萃剂鼎医药提交了瑞舒伐他汀依折麦布片（I）的4类仿制上市申请。瑞舒伐他汀依折麦布片（I）是血脂调节复方制剂潜力产品，赛诺菲的原研产品2025年Q1在中国三大终端六大市场飙涨29239%。目前，新华制药暂无血脂调节复方制剂获批，公司有望开拓新市场。图1：新华制药最新申报的产品来源：CDE官网瑞舒伐他汀依折麦布片（I）是由瑞舒伐他汀（HMG-CoA还原酶抑制剂）和依折麦布（选择性胆固醇吸收抑制剂）两种作用机制互补的降脂药组成的复方制剂，两者联用能够在他汀基础上进一步加强降脂作用，提升血脂达标率，该药品适用于高胆固醇血症及纯合子型家族性高胆固醇血症。米内网数据显示，原研药企赛诺菲在2023年12月获批进口，北京福元医药在2025年4月拿下国内首仿，随后天宇股份、石家庄四药陆续获批，新华制药将参与瑞舒伐他汀依折麦布片（I）国产第四家之争。图2：赛诺菲的瑞舒伐他汀依折麦布片（I）销售情况（单位：万元）来源：米内网格局数据库在中国三大终端六大市场（统计范围见文末），原研的瑞舒伐他汀依折麦布片（I）2025年Q1大涨接近29239%，一跃成为血脂调节复方制剂TOP2产品。图3：新华制药已上市的血脂调节剂来源：米内网中国上市药品（MID）数据库截至目前，新华制药已有5款血脂调节剂上市销售，包括了HMGCoA还原酶抑制剂（阿托伐他汀钙片、瑞舒伐他汀钙片）、烟酸及其衍生物（烟酸片、甘露醇烟酸酯片）、其他血脂调节剂（二十碳五烯酸乙酯软胶囊），暂无血脂调节复方制剂获批。瑞舒伐他汀依折麦布片（I）是新华制药首款申报上市的血脂调节复方制剂，有望为公司开拓新市场，并进一步助力公司提升在血脂调节剂市场的竞争力。2024年在中国三大终端六大市场，血脂调节剂（化+生）的销售规模在240亿元以上。表1：今年以来新华制药获批的新产品来源：米内网中国上市药品（MID）数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2560416923","isCrawlerRequest":true}